NAMS compared with AURA: revenue, margins and what each company keeps, and the suppliers and customers both name

NAMSNewAmsterdam Pharma Co N.V.

Mkt capRevenueRevenue

AURAAura Biosciences, Inc.

Mkt capRevenueRevenue

Compare

NAMSNewAmsterdam Pharma Co N.V.

AURAAura Biosciences, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NAMS1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±12.6%▼−0.47%×0.04

AURA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±83.3%▲+4.42%×0.05

May 12 '26±49.3%▼−3.17%×0.06

= impliedNAMS realized, solidAURA realized, hatchedOne scale, both sides: full bar = 84%× = |realized| ÷ impliedSource: market data

May 5 '26

±44.7%

▲+6.59%

×0.15

Q1 FY26±64.1%▼−1.12%×0.02

NAMSNewAmsterdam Pharma Co N.V.

19.91▲+1.77%· post 19.91

Mkt cap$2.4BRevenue$4MQ2 FY26Revenue$23MFY25

AURAAura Biosciences, Inc.

6.25▲+3.59%· post 6.25

ClosedNov 3 '26

Mkt cap$625.3MRevenue—Revenue—

Compare

ClosedNov 3 '26

NAMSNewAmsterdam Pharma Co N.V.

AURAAura Biosciences, Inc.

19.91▲+1.77%post 19.91

Price

6.25▲+3.59%post 6.25

$2.4B

Mkt cap

$625.3M

Q2 FY26$4M

Revenue

—

FY25$23M

Revenue

—

NAMS19.91▲+1.77%vsAURA6.25▲+3.59%ClosedNov 3 '26